• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ICU Investors Have Opportunity to Lead SeaStar Medical Holding Corporation Securities Fraud Lawsuit with the Schall Law Firm

By: Schall Law via GlobeNewswire
August 20, 2024 at 11:00 AM EDT

LOS ANGELES, Aug. 20, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation (“SeaStar” or “the Company”) (NASDAQ: ICU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between October 31, 2022 and March 26, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before September 6, 2024.        

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. SeaStar failed to maintain adequate controls over its HDA application to the FDA. The FDA was unlikely to approve the HDA application due to deficiencies. The Company downplayed the extent of these deficiencies. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about SeaStar, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE:

 The Schall Law Firm


Primary Logo

More News

View More
GM's Billion-Dollar Bruise: GM's Strategic Pivot Makes It a Buy
Today 18:09 EDT
Via MarketBeat
Topics Electric Vehicles
Tickers GM
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Today 16:15 EDT
Via MarketBeat
Topics World Trade
Tickers LLY NVO SEPN
ASML Can Hit New Highs, But It Won’t Be Easy: Here’s Why
Today 16:03 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers ASML
Vertiv Stock Surges on Strategic CFO Hire and AI Momentum
Today 15:41 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers NVDA VRT WAB
Tempus AI Hits $100—Are Shares Due for a Pullback?
Today 13:49 EDT
Via MarketBeat
Topics Artificial Intelligence Government Initial Public Offering
Tickers TEM
Recent Quotes
View More
Symbol Price Change (%)
GOOG  251.71
+5.52 (2.24%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap